- Conditions
- Renal Impairment
- Interventions
- MBX 2109
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Miami, Florida • Tampa, Florida • Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy
- Interventions
- MBX 2109 (Part A), MBX 2109 (Part B), Placebo
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin
- Conditions
- Hypoparathyroidism
- Interventions
- Canvuparatide, Placebo
- Drug · Other
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 12
- States / cities
- Homestead, Florida • Metairie, Louisiana • Las Vegas, Nevada + 9 more
- Conditions
- Hypoparathyroidism
- Interventions
- MBX 2109, Placebo
- Drug · Other
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 27
- States / cities
- Sacramento, California • Jacksonville, Florida • Miami, Florida + 22 more
- Conditions
- Hypoparathyroidism
- Interventions
- 400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Miami, Florida • Macon, Georgia • Jackson, Mississippi + 14 more